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Rationale: Multiple infections with different strains of Mycobacterium
tuberculosis may occur in settings where the infection pressure is
high. The relevance of mixed infections for the patient, clinician,
and control program remains unclear. Objectives: This study aimed
to describe reinfection and mixed infection as underlying mecha-
nisms of changing drug-susceptibility patterns in serial sputum cul-
tures. Methods: Serial M. tuberculosis sputum cultures from patients
diagnosed with multi-drug-resistant (MDR) tuberculosis were eval-
uated by phenotypic drug-susceptibility testing and mutation de-
tection methods. Genotypic analysis was done by IS6110 DNA fin-
gerprinting and a novel strain-specific polymerase chain reaction
amplification method. Measurements and Main Results: DNA finger-
printing analysis of serial sputum cultures from 48 patients with
MDR tuberculosis attributed 10 cases to reinfection and 1 case
to mixed infection. In contrast, strain-specific polymerase chain
reaction amplification analysis in 9 of the 11 cases demonstrated
mixed infection in 5 cases, reinfection in 3 cases, and laboratory
contamination in 1 case. Analysis of clinical data suggests that first-
line therapy can select for a resistant subpopulation, whereas poor
adherence or second-line therapy resulted in the reemergence of
the drug-susceptible subpopulations. Conclusions: We have shown
that, in some patients with MDR tuberculosis, mixed infection may
be responsible for observations attributed to reinfection by DNA
fingerprinting. We conclude that treatment and adherence deter-
mines which strain is dominant. We hypothesize that treatment
with second-line drugs may lead to reemergence of the drug-sus-
ceptible strain in patients with mixed infection.
Keywords: drug resistance; mixed infections; Mycobacterium tuberculo-
sis; reinfection
Traditionally, infection by Mycobacterium tuberculosis was as-
sumed to be caused by a single strain, and recurrences were
believed to be due to reactivation of the strain that caused the
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first episode (1). Infection with multiple M. tuberculosis strains
within one patient before, during, or after successful treatment
was rarely considered. The development of DNA fingerprinting
methods to differentiate M. tuberculosis strains (2) has made it
possible to document reinfection with a genetically different M.
tuberculosis strain in patients with recurrent tuberculosis who
were resident in high or low tuberculosis incidence settings,
and who were either immunocompetent or immunosuppressed
(3–11).
Evidence of mixed infection in a single host at a single point
in time, suggesting reinfection before or during disease, was first
observed using the phage typing method (12, 13) and was later
confirmed using DNA fingerprint analysis (8, 14–19). The infre-
quency of observing mixed infections probably reflects the insen-
sitivity of the DNA fingerprinting method (16). It has recently
been shown, using a highly specific polymerase chain reaction
(PCR)–based genotyping method, that patients with tuberculosis
in a high-incidence setting often have different M. tuberculosis
strains in the same sputum specimen (20).
It has been suggested that mixed infections may be of concern
for tuberculosis control because such infections could influence
the diagnosis of drug resistance if a patient is infected with both
a sensitive and a resistant strain (21). Furthermore, it is possible
that undetected drug-resistant strains may emerge under the
pressure of antibiotic treatment (21).
This study aimed to describe whether reinfections and mixed
infections can be underlying mechanisms of drug-susceptibility
variation in serial M. tuberculosis sputum cultures collected from
patients diagnosed with multi-drug-resistant (MDR) tuberculo-
sis (defined as bacillary resistance to at least isoniazid and rifam-
pin). We show that the type of information available (clinical,
microbiological, DNA fingerprinting, or PCR results) influences
the interpretation of the observed variation in drug-susceptibility
patterns. We demonstrate how the selective pressure of the anti-
biotic therapy determines which strain is dominant in the sputum
culture. This work was presented at the South African Society
for Biochemistry and Molecular Biology conference held in Stel-
lenbosch, South Africa, in 2005 (31).
METHODS
Study Population
Clinical data and sputum specimens were collected as part of an ongo-
ing, prospective study in Cape Town, South Africa (22). The incidence
of new smear and/or culture-positive tuberculosis in the study communi-
ties (population,  35,000) was, on average, 313 per 100,000 per year
(1993–1998) (22). A database search was performed to identify patients
with MDR tuberculosis and who had at least two serial sputum cultures
of M. tuberculosis. Only data from patients fulfilling these criteria were
included in the analysis. This study was approved by the Ethics Review
Board at Stellenbosch University.
Drug-Susceptibility Testing
Drug-susceptibility testing was done by the National Health Laboratory
Service using the indirect proportion method on Löwenstein-Jensen
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TABLE 1. PRIMER SEQUENCES
Primer Name Sequence IS6110 Insertion Point
Universal forward TTC AAC CAT CGC CGC CTC TAC
Strain a reverse GAG CGC GCC GAA GGC GGC CAT GAA C 2602188
Strain b reverse GGC CAA ATC CAG CAC CAC GGT GAA C 3096762
Strain c reverse GCG CCA ATG AAG CCA GCA ACG CCG T 3379767
Strain d reverse CAC CCT CTA CTC TGC GCT TTG 3127922
Strain e reverse TTG CTT TGA GGC GAC TTC C 3125705
Strain f reverse GCG CGT GTC CCGA TGT GAG GTG GT 1989058
Strain g reverse TCA GCC CGC CGC GAC TGT ATG AAC C 2627510
Strain h reverse CAG GAC AAA GGT CGG CAA CCT GAA CC 1996100
Internal control forward GAG CAG CAG TGG AAT TTC GC
Internal control reverse TCC CAG TGA CGT TGC CTT C
medium containing critical concentrations of 0.2 g/ml isoniazid and
30 g/ml rifampin. Drug-susceptibility testing for other drugs was done
for sputum cultures resistant to isoniazid and/or rifampin.
Mutations conferring resistance to isoniazid, rifampin, streptomycin,
and ethambutol were determined by DNA sequencing or PCR dot-
blot hybridization (23).
Genotyping by Molecular Techniques
M. tuberculosis strains present in serial sputum cultures were genotyped
by the IS6110 DNA fingerprinting method (2). In addition, each sputum
culture was assessed by strain-specific PCR amplification (20), using a
universal forward primer (complementary to an internal sequence of
the IS6110 element) in combination with the respective reverse primer
(complementary to the strain-specific IS6110 insertion junction;
Table 1). Strain-specific primers were designed after sequencing of the
IS6110 insertion junctions from different strains identified in serial
sputum cultures by DNA fingerprinting (see the online supplement).
PCR reactions were performed in a total volume of 25 l, according to
previously described reaction conditions (20). PCR-amplified products
were electrophoretically fractionated in 2.0% agarose and visualized
by staining with ethidium bromide. Sensitivity and specificity of each
primer set were determined by amplification of pure DNA from a panel
of genetically unrelated and related strains (20), and were shown to be
100% (95% confidence interval, 85–100%) when compared with the
gold standard of IS6110 DNA fingerprinting. Using the described ampli-
fication conditions (20), underlying strains could be detected at a molar
ratio of 1:125.
To minimize laboratory cross-contamination, sputum cultures from
each patient were PCR-amplified on separate days, and each procedure
(preparation of the PCR reaction mixes, the addition of the DNA, the
PCR amplification, and the electrophoretic fractionation) was con-
ducted in physically separated rooms. Primers complementary to the
M. tuberculosis gene Rv3875 were included in each amplification reac-
tion as a positive amplification control. Negative controls (water) were
included to detect reagent contamination.
Reagent contamination could not be detected because all negative
controls were negative on amplification. The inability to detect specific
strains was not due to the presence of PCR inhibitors because positive
controls produced amplification products in all sputum cultures. This
PCR method was highly consistent as amplification of each sputum
culture gave identical products on repeated amplification.
Definitions of Reinfection and Mixed Infection
Reinfection was confirmed, according to the gold standard (5), when
analysis of serial sputum cultures from a single patient showed the
appearance of a genetically different strain (in two or more cultures)
during the course of disease. If the genetically different strain was
only identified in a single sputum culture, reinfection was considered as
probable. Mixed infection was confirmed when two genetically distinct
strains were present in the initial sputum culture as well as in at least
one subsequent sputum culture.
Statistical Methods




During the period from January 1993 to December 1998, 1,023
patients resident in the epidemiologic field site in Cape Town,
South Africa, were culture-positive for M. tuberculosis (22). Spu-
tum cultures from 768 of these patients were available for further
analysis. Cultures from the remaining 255 patients were contami-
nated, were lost, or failed to produce usable DNA fingerprints.
Phenotypic drug-susceptibility testing classified 48 of the 768
patients as having an episode of MDR tuberculosis.
Genotyping by DNA Fingerprinting
DNA fingerprinting showed a single strain in serial sputum cul-
tures from 37 of the 48 patients with MDR tuberculosis. Serial
sputum cultures from the remaining 11 patients showed the
presence of genetically distinct strains (Figure 1). Among these,
two different strains were isolated from one patient (Patient 2)
on the day of diagnosis, as well as from subsequent sputum
cultures, demonstrating mixed infection (Figure 2). In the re-
maining 10 patients, DNA fingerprinting data suggested reinfec-
tion. Reinfection could be confirmed by using fingerprint meth-
ods in two patients (HIV-uninfected Patient 1 [Figure 2] and
HIV-infected Patient 7 [Table 2]), and was suggested (probable
reinfection) in the remaining eight patients, for whom confirma-
tory sputum cultures for both genetically distinct M. tuberculosis
strains were not available.
Genotyping by PCR Amplification
According to the strain-specific PCR amplification method re-
sults, only 3 of the 11 patients with genetically distinct strains
present on DNA fingerprint analysis were classified as confirmed
or probable reinfection (Figure 1). Reinfection with an MDR
strain during treatment with first-line antituberculous drugs was
confirmed in Patient 7, an HIV-infected patient (Table 2). Re-
infection could not be distinguished from mixed infection in the
remaining two patients (Table 2, Patients 3 and 4) because their
initial sputum culture was not available for genotypic analysis.
Five cases were classified as mixed infection based on analysis
of the strain-specific PCR amplification results. The diagnosis
of mixed infection on the basis of the DNA fingerprinting results
in Patient 2 was confirmed by the PCR method (Figures 1 and
2). In addition, four patients classified as probable reinfection by
DNA fingerprinting were reclassified as cases of mixed infection,
because two genetically distinct strains could be identified by
PCR in both the initial and subsequent sputum cultures (Figure 2
and Table 2; Patients 1, 5, 6, and 8).
In one patient classified as probable reinfection by the DNA
fingerprinting method, the presence of a second strain could not
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Figure 1. Schematic diagram showing
the grouping of patients according to
DNA fingerprinting and strain-specific
polymerase chain reaction (PCR) amplifi-
cation methods. †Sputum culture from
two patients could not be tested. MDR 
multi-drug-resistant.
be confirmed by PCR amplification in more than one sputum
culture (data not shown), suggesting laboratory error (Figure 1).
Strain-specific primers were not available for the analysis of
serial sputum cultures from the remaining two patients. Similarly,
strain-specific primer sets were also not available for the 37
patients with MDR tuberculosis with genetically identical strains
in serial sputum cultures, because the development of primers
was dependent on the identification of different M. tuberculosis
strains in serial sputum cultures.
Clinical and Demographic Characteristics of Patients with
Mixed Infection and Reinfection
No difference could be found between patients infected with
either a single or two genetically distinct strains, when comparing
sex, age, type of tuberculosis, and treatment outcome (Table 3).
Mechanisms for Emergence and Reemergence of Strains in
M. tuberculosis Sputum Cultures of Mixed Infection Cases
To explore for an association between treatment regimen, adher-
ence, and changing strain populations during therapy in patients
with MDR tuberculosis, the genotype data were compared with
the drug-susceptibility patterns, the treatment regimen, and the
adherence records (Figure 2 and Table 2).
Emergence of a drug-resistant strain on treatment with first-
line antituberculosis drugs. Analysis of the drug-susceptibility
results of the sputum cultures of Patient 1 (Figure 2, Patient 1,
lane A through D) shows fully susceptible initial sputum cultures
followed by the appearance of MDR tuberculosis. Without addi-
tional information of genotypic data, this would have been inter-
preted as acquisition of drug resistance in the same strain. Con-
versely, according to the analysis of the DNA fingerprinting
data, this patient would have been classified as confirmed reinfec-
tion with a genetically distinct MDR strain during therapy
(Figure 2, Patient 1; compare lanes A and B to lanes C and D).
In contrast to this, the PCR-based method showed that both the
drug-susceptible and the MDR strains were present at diagnosis
(Figure 2, Patient 1, lane A), classifying the patient as a case of
mixed infection. These findings suggest that antibiotic pressure
with a standard first-line regimen may have led to reduced
growth of the drug-susceptible strain population, and selection
and subsequent culture dominance of the previously undetected
genetically distinct MDR strain population. Similar results were
observed for Patient 2 (Figure 2), as well as Patients 5 and 6
(Table 2).
Treatment interruption and reemergence of a drug-susceptible
strain in the patient with MDR tuberculosis. Analysis of the drug-
susceptibility results of the subsequent sputum cultures from
Patient 1 shows the reemergence of drug-susceptible sputum
cultures (Figure 2, Patient 1, lanes E and F) followed again by
MDR tuberculosis (Figure 2, Patient 1, lanes G to I). Without
additional information, the presence of the drug-susceptible
strain would have been interpreted as inaccuracy of the pheno-
typic drug-susceptibility tests. Analysis of DNA fingerprinting
data, however, confirms the presence of the drug-susceptible
strain (the strain the patient was initially dually infected with),
thereby refuting the hypothesis of inaccuracy of the phenotypic
drug-susceptibility tests. The PCR-based method showed that
both the drug-susceptible and the MDR strain were present
throughout the 17-month treatment period. These results have
demonstrated that in this patient with MDR tuberculosis, the
underlying drug-susceptible strain reemerged and became the
dominant strain population in the sputum cultures after partial
or complete removal of the antibiotic pressure through poor
adherence or default (Figure 2, Patient 1, lane D). The data for
Patients 3 and 8 showed a similar pattern, with the underlying
drug-susceptible strain reemerging after a period of poor treat-
ment adherence or default (Table 2, Patient 3, lane J and K,
and Patient 8, lane C and D).
Treatment with second-line drugs and reemergence of a drug-
susceptible strain in a patient with MDR tuberculosis. Analysis
of the drug-susceptibility results of the sputum cultures from
Patient 2 shows the presence of drug-susceptible and drug-resis-
tant strains at time of diagnosis (Figure 2, Patient 2, lanes A
and B). Without additional information, this would have been
interpreted as inaccuracy of the phenotypic drug-susceptibility
tests. Analysis of DNA fingerprinting data and PCR-based data
confirmed the presence of both a drug-susceptible and a drug-
resistant strain at diagnosis, indicating mixed infection. Three
months after starting second-line treatment, the drug-susceptibil-
ity tests demonstrate the presence of a fully susceptible sputum
culture (Figure 2, Patient 2, lane F), which was confirmed by
DNA fingerprinting and PCR-based genotyping methods. To-
gether, these results suggest that, in this patient, the lowered
antibiotic pressure was not due to poor adherence (adherence
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Figure 2. Phenotypic and genotypic characterization of sputum cultures from Patients 1 and 2. Serial M. tuberculosis sputum cultures were obtained
from patients diagnosed with MDR tuberculosis. Phenotypic culture-based drug-susceptibility testing was performed by the direct proportion
method. Treatment regimen implemented at each visit is indicated, whereas adherence was measured for the period between each visit. Mutations
conferring resistance were detected by DNA sequencing or PCR dot blot (23). All sputum cultures were genotyped by IS6110 DNA fingerprinting
(2), and the strain(s) present was randomly assigned an alphabetic designation according to its strain family classification. Presence of multiple
strains in each sputum culture was determined using strain-specific PCR amplification (20). D  default (stopped therapy for a period of  2
months); Emb  ethambutol; Eth  ethionamide; Inat  isoniazid and thiacetazone; Inh  isoniazid; Kana  kanamycin; nd  not determined;
neg  negative; Oflox  ofloxacin; pos  positive; Pza  pyrazinamide; R  drug resistant; Rif  rifampin; S  drug sensitive; Sm  streptomycin;
Teri  terizidone; thia  thiacetazone; U  unknown;   mutation present;   mutation absent; *internal positive PCR control (Rv3875).
was 92 to 100% throughout treatment) but rather due to treat-
ment with less effective second-line drugs. A similar result was
observed for Patient 4 (Table 2).
The analysis of the combined data (clinical, phenotypic drug
susceptibility test, mutation detection analysis, IS6110 DNA fin-
gerprinting analysis, and strain-specific PCR amplification) al-
lowed most observations to be resolved; however, some results
remained discordant. In all of these instances, the phenotypic
drug-susceptibility test data were in conflict with the results of
mutation analysis. In three cases, the culture-based phenotyping
method failed to detect the presence of the drug-resistant strain,
despite this strain being overrepresented in these cultures
(Table 2, Patients 3, lanes B and H, 4, lane F, and 7, lane C).
This result demonstrates poor-quality drug-susceptibility testing.
In the remaining two cases, the mutation analysis failed to detect
the presence of the drug-resistant strain, probably as a result of
the preferential amplification of the overrepresented genomic
locus of the drug-susceptible strain in comparison to the under-
represented genomic locus in the underlying drug-resistant strain
(Table 2, Patients 6, lane A, and 8, lane D).
DISCUSSION
The use of the standard IS6110 DNA fingerprinting method has
provided insight into the relative importance of recent infection
and reactivation (24, 25) and has established reinfection as a
mechanism leading to the recurrence of tuberculosis (3, 5, 9).
DNA fingerprinting has also been used to gain insight into the
mechanisms resulting in changing drug-susceptibility patterns
during the course of disease (17, 26, 27). These studies have
demonstrated that reinfection, before or during therapy, can be
a mechanism leading to the development of drug resistance.
Using DNA fingerprinting as the gold standard, our study sup-
ports reinfection as a mechanism leading to changing drug-sus-
ceptibility patterns.
Our PCR-based strain-typing method, challenged, in certain
instances, the validity of the interpretation based on the DNA
fingerprinting data. The only patient with confirmed reinfection
by both methods was coinfected with HIV and therefore was
probably unable to resist reinfection with a drug-resistant strain
despite receiving therapy for the drug-susceptible tuberculosis
(4). The PCR-based strain-typing method contested the DNA
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TABLE 2. SUMMARY OF THE PHENOTYPIC AND GENOTYPIC CHARACTERISTICS OF SPUTUM CULTURES
FROM PATIENTS 3 TO 8
Patient 3 (HIV neg) Patient 4 (HIV neg)
A B C D E F G H I J K L M A B C D E F G H
Day U 25 20 16 29 05 09 31 29 04 15 05 14 U 14 09 20 21 28 05 08
Month 11 05 07 08 09 10 11 01 02 04 10 02 08 11 04 06 06 07 07 01 06
Year 94 95 95 95 95 95 95 96 96 96 96 98 98 93 94 94 94 94 94 95 95
Susceptibility
Isoniazid nd R R R R R R S R R S R R R R S R R S R R
Rifampin nd S R R R R R S R R S R R R R S R R S R R
Treatment
Rifafour (Inh, Rif, Pza, Emb) U X X X X X
Rifater (Inh, Rif, Pza) X
Emb, Eth, Inat, Kana X X X X X X X
Emb, Eth, Inat, Kana, Teri X
Eth, Inat, Kana, Teri, X X X X
Emb, Eth Inat, X
Emb, Eth, Inat, Teri, Pza X
Adherence, % U 87 79 90 90 95 99 71 79 53 49 D U 83 80 82 100 100 68 57
Point mutations
katG315 nd             nd       
rpoB531 nd       
rpoB516 nd            
Strain designation
(DNA fingerprinting) nd b b b b b b b b b e b b nd d f d d d d d
Strain population
present (PCR) nd b b b b b b  e b b b  e b  e b b nd d  f f d d  f d d  f d
Patient 5 (HIV nd) Patient 6 (HIV nd) Patient 7 (HIV pos) Patient 8 (HIV nd)
A B C D A B C A B C D E F A B C D
Day 03 26 05 05 17 23 10 01 02 07 15 15 21 19 24 24 05
Month 06 11 01 01 06 09 11 07 07 12 12 12 12 02 02 02 03
Year 93 93 95 95 93 93 93 98 98 98 98 98 98 98 98 98 99
Susceptibility
Isoniazid S nd R R R R R nd nd S R R R nd R R R
Rifampin S nd R R R R R nd nd S R R R nd R R R
Treatment
Rifater (Inh, Rif, Pza) X X X X
Emb, Eth, Kana, Inat, Oflox,
Sm, Teri, Pza X X X
Rifinah (Inh, Rif) X X X X X
Emb, Pyrifin (Inh, Rif, Pza) X X
Emb, Eth, Sm, Inat, Pza X
Adherence, % U 78 78 97 U 95 85 85 100 38 D
Point mutations
KatG315                 
rpoB531                 
Strain designation
(DNA fingerprinting) g d d d h b b e e d d d d c c c e
Strain population
present (PCR) g  d g  d g  d g  d b  h b b  h e e d  e d  e d  e d  e c c  e c c  e
Definition of abbreviations: D  default (stopped therapy for a period of  2 months); Emb  ethambutol; Eth  ethionamide; Inat  isoniazid and thiacetazone;
Inh  isoniazid; Kana  kanamycin; nd  not determined; neg  negative; Oflox  ofloxacin; PCR  polymerase chain reaction; pos  positive; Pza  pyrazinamide;
R  drug resistant; Rif  rifampin; S  drug sensitive; Sm  streptomycin; Teri  terizidone; U  unknown;   mutation present;   mutation absent.
For complete dataset, see online supplement (Figure E1).
fingerprinting classification of reinfection in certain cases by
demonstrating the presence of undetected drug-resistant strains
(not detected by drug-susceptibility testing or DNA fingerprint-
ing) in the initial sputum culture. It is unlikely that these results
reflect cross-contamination because the strains causing mixed
infection were found to be present in multiple sputum cultures
taken from these patients on different occasions. Only one isolate
from one patient was classified as cross-contamination. This level
of cross-contamination is similar to the 3.8% previously de-
scribed for this laboratory (19).
We present new data to support three mechanisms whereby
mixed infections can lead to changing drug-susceptibility pat-
terns during therapy. We suggest first that, during the initial
treatment period, the first-line antibiotics reduced the drug-sus-
ceptible strain population, while allowing the drug-resistant
strain population to grow, thereby converting the patient from
an apparently drug-susceptible tuberculosis case to an MDR
tuberculosis case. We propose that this represents a mechanism
of selection through antibiotic pressure.
Second, when the antibiotic pressure was removed by poor
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TABLE 3. CHARACTERISTICS OF PATIENTS DIAGNOSED
WITH MULTI-DRUG-RESISTANT TUBERCULOSIS
BETWEEN 1993 AND 1998
Single DNA Multiple DNA
Fingerprint, % Fingerprints, %*
(n  37) (n  10) p Value
Male 51 50 1.00
Mean age, yr 30.8 36.8 0.22
Disease classification
Pulmonary TB 95 100 1.00
Primary TB 5 0
Treatment history
New 51 40 0.72
Retreatment 49 60
HIV status








Culture negative 59 60 0.68
Culture positive 22 10
Death 14 20
Unknown 5 10
Definition of abbreviation: TB  tuberculosis.
* One patient for whom the sputum culture was identified as laboratory error
by strain-specific polymerase chain reaction method was omitted from this group.
adherence or default, the underlying drug-susceptible strain pop-
ulation reemerged as the dominant population. This suggests a
mechanism of selection in the absence of antibiotic pressure. The
reason for the observed “overgrowth” by the drug-susceptible
population remains unknown. We propose that this could reflect
a difference in the level of “fitness” between the drug-susceptible
and drug-resistant populations present in these patients. Similar
observations were made when drug-susceptible and drug-resis-
tant populations were cultured in vitro and in macrophage cell
lines (28, 29). The reemergence of the drug-susceptible popula-
tion demonstrates that the initial period of therapy in these
patients was insufficient to enable complete sterilization. This
supports the need to ensure adherence over the full course of
therapy.
Third, we observed the reemergence of the underlying drug-
susceptible strain population when the antibiotic pressure was
changed by the introduction of second-line therapy. It is well
known that second-line antibiotics have lower bactericidal activi-
ties when compared with first-line antibiotics and therefore we
propose a mechanism of selection due to a reduced antibiotic
pressure. This study supports the suggestion by Post and cowork-
ers (30) that the treatment of patients with MDR tuberculosis
may require antibiotics which target both drug-susceptible and
drug-resistant subpopulations.
Comparison of the clinical parameters between patients in-
fected with a single strain or multiple strains did not identify
significant differences. However, because this study was not de-
signed to detect a difference between these patient groups and
precludes the period of disease before diagnosis, we cannot make
definite conclusions on the influence of mixed infection on the
disease presentation, disease progression, or treatment outcome.
Most important, this study demonstrates the inability of routine
culture-based drug-susceptibility methods to identify the pres-
ence of underlying drug-resistant strains, which is of concern for
the patient and their contacts. Diagnostic delays could prolong
the implementation of an appropriate treatment regimen and
thereby extend the window of opportunity for transmission. Fur-
thermore, inappropriate therapy during the period in which
drug-susceptibility testing is being done could enhance the risk
of the drug-resistant strain acquiring additional resistance muta-
tions.
We acknowledge that the conclusions drawn from this study
are limited by the small number of patients, although, with this
study, we did not aim to provide a measure of the frequency of
these processes but rather to demonstrate the mechanisms and
the fact that they are able to occur in an epidemic setting. It is,
however, warranted that our hypothesis generated on the basis
of a limited number of observations be confirmed in different
geographic settings.
In conclusion, this study describes the first molecular analysis
of the population structure of drug-resistant and drug-suscepti-
ble M. tuberculosis strains in serial sputum cultures during the
course of MDR tuberculosis. We have demonstrated that mixed
infection is an important mechanism underlying changing drug-
susceptibility patterns in a high-incidence region. Drug-suscepti-
bility patterns change through the presence or absence of anti-
biotic pressure, which determines the dominant growth of the
coinfecting strain. The inability to accurately determine resis-
tance patterns in cases of mixed infection may exacerbate delays
in the diagnosis of drug-resistant tuberculosis, which could have
implications for the individual patient and the spread of drug-
resistant strains.
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